Accurate diagnosis coding is essential for clinical documentation, billing, and cancer surveillance. ICD-10 codes for bladder cancer provide a standardized framework that enables healthcare providers to specify tumor location, histology, and behavior with precision. This guide covers every major code category, subsite classification, staging considerations, and histological distinctions that coders and clinicians encounter in practice.
Key Takeaways
- Bladder cancer codes in ICD-10-CM fall primarily under category C67, with subcodes specifying anatomical subsites.
- The malignant neoplasm of bladder ICD-10 code range (C67.0–C67.9) covers all major tumor locations within the bladder wall.
- Transitional cell carcinoma (urothelial carcinoma) is the most common bladder cancer histology and requires accurate morphology coding alongside the C67 category code.
- Staging information, while captured in TNM systems, informs—but does not replace—the ICD-10 diagnosis code selection.
- Secondary and in situ bladder neoplasms carry distinct ICD-10 codes separate from primary malignancies.
ICD-10 Codes for Bladder Cancer: Full Code List by Tumor Type
The bladder cancer ICD-10 classification guide organizes primary malignant neoplasms of the bladder under category C67 in ICD-10-CM. This category is subdivided according to the anatomical subsite of the tumor, allowing coders to document exactly where within the bladder the malignancy arises. In addition to primary malignancies, related codes address in situ lesions, benign neoplasms, and secondary (metastatic) disease, each carrying distinct clinical and billing implications.
Beyond category C67, coders frequently reference D09.0 for carcinoma in situ of the bladder, which represents a non-invasive high-grade lesion that has not penetrated the basement membrane. Secondary malignant neoplasm of the bladder, meaning metastatic spread to the bladder from another primary site, is coded as C79.11. Understanding the distinction between these categories is critical to avoiding claim denials and ensuring accurate cancer registry data.
The following table provides a consolidated reference for the most commonly used ICD-10 codes related to bladder cancer, organized by clinical scenario:
| ICD-10 Code | Description | Clinical Scenario |
|---|---|---|
| C67.0 | Malignant neoplasm of trigone of bladder | Primary tumor at the trigone |
| C67.1 | Malignant neoplasm of dome of bladder | Primary tumor at the dome |
| C67.2 | Malignant neoplasm of lateral wall of bladder | Primary tumor on lateral wall |
| C67.3 | Malignant neoplasm of anterior wall of bladder | Primary tumor on anterior wall |
| C67.4 | Malignant neoplasm of posterior wall of bladder | Primary tumor on posterior wall |
| C67.5 | Malignant neoplasm of bladder neck | Tumor involving the internal urethral orifice |
| C67.6 | Malignant neoplasm of ureteric orifice | Tumor at the ureter opening |
| C67.7 | Malignant neoplasm of urachus | Tumor of urachal remnant |
| C67.8 | Malignant neoplasm of overlapping sites of bladder | Tumor spanning multiple subsites |
| C67.9 | Malignant neoplasm of bladder, unspecified | Site not documented |
| D09.0 | Carcinoma in situ of bladder | Non-invasive high-grade lesion |
| C79.11 | Secondary malignant neoplasm of bladder | Metastatic disease to the bladder |
Malignant Neoplasm of Bladder ICD-10 Classification and Subsites
The malignant neoplasm of bladder ICD-10 code category C67 reflects the anatomical complexity of the bladder. Each subsite code corresponds to a distinct region of the bladder wall or associated structures. Clinicians performing cystoscopy and pathologists reviewing biopsy specimens provide the subsite information necessary for accurate code assignment. When the operative or pathology report identifies a specific location, coders should always select the most precise subsite code available rather than defaulting to C67.9 (unspecified).
According to the World Health Organization (WHO), bladder cancer accounts for approximately 573,000 new cases and 212,000 deaths globally each year, making it one of the ten most common cancers worldwide. This epidemiological burden underscores why precise classification matters—both for individual patient management and for population-level cancer surveillance. Inaccurate or non-specific coding inflates the C67.9 (unspecified) category, which obscures subsite trends that researchers and public health agencies rely on.
One nuance worth noting involves tumors that overlap two or more adjacent subsites of the bladder. In such cases, C67.8 (overlapping sites) is the appropriate code rather than coding each subsite separately. The ICD-10-CM guidelines specify that overlapping lesion codes apply when the point of origin cannot be determined, reinforcing the importance of reviewing imaging and operative notes before finalizing code selection.
How to Code Bladder Cancer in ICD-10 Based on Staging and Histology
Bladder cancer staging and ICD-10 coding intersect in ways that require coders to understand both systems. The TNM staging system—developed jointly by the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC)—classifies bladder cancer from stage 0 (non-invasive) through stage IV (distant metastasis). ICD-10-CM does not contain separate codes for each TNM stage; instead, staging data are recorded using additional codes from the Z-code range or captured in cancer registry fields.
For non-invasive papillary carcinoma (Ta) and carcinoma in situ (Tis), the correct ICD-10-CM code is D09.0, not a C67 code, because these lesions have not crossed the basement membrane and are classified as in situ rather than invasive. Once a tumor invades the lamina propria (T1) or beyond, the appropriate C67 subsite code applies. This distinction is clinically significant and directly affects treatment decisions, as muscle-invasive disease typically requires more aggressive management than non-muscle-invasive disease.
Histological type also plays a role in complete documentation, though ICD-10-CM diagnosis codes do not encode histology directly. Histology is captured through ICD-O-3 (International Classification of Diseases for Oncology, third edition) morphology codes used in cancer registries. For billing and clinical records, the C67 or D09.0 diagnosis code is paired with documentation in the pathology report that specifies the histological subtype, ensuring a complete clinical picture for downstream data users.
- Non-invasive papillary carcinoma (Ta): Coded as D09.0 (carcinoma in situ), as the lesion remains above the basement membrane.
- Carcinoma in situ (Tis): Also coded as D09.0; represents flat, high-grade non-invasive disease.
- T1 and higher (invasive disease): Coded with the appropriate C67.x subsite code based on documented tumor location.
- Metastatic bladder cancer: The primary site retains a C67.x code; secondary sites use the corresponding secondary malignancy code (e.g., C79.11 for bladder as a secondary site, or C77–C79 for other metastatic locations).
ICD-10 Coding for Transitional Cell Carcinoma and Other Bladder Cancer Types
ICD-10 codes for transitional cell carcinoma bladder follow the same C67 category structure used for all primary bladder malignancies, because ICD-10-CM diagnosis codes do not differentiate histological subtypes within the C67 range. Transitional cell carcinoma—now more precisely termed urothelial carcinoma—accounts for roughly 90% of all bladder cancers diagnosed in the United States, according to the American Cancer Society. The ICD-O-3 morphology code 8120/3 identifies this histology for registry purposes, while the C67 subsite code serves billing and clinical documentation needs.
Other bladder cancer histologies are less common but clinically important. Squamous cell carcinoma of the bladder, which comprises approximately 3–5% of cases in Western countries and is associated with chronic inflammation or schistosomiasis, is documented using the same C67 subsite codes as urothelial carcinoma. The histological distinction is recorded in the pathology report and ICD-O-3 morphology code rather than the ICD-10-CM diagnosis code. Adenocarcinoma of the bladder, including urachal adenocarcinoma arising from C67.7, follows the same coding logic.
Small cell carcinoma and other rare neuroendocrine tumors of the bladder represent a distinct clinical challenge. These aggressive tumors share the C67 code category but require thorough documentation given their markedly different prognosis and treatment pathway compared to urothelial carcinoma. Coders should ensure that pathology reports are reviewed carefully and that any additional codes—such as those for paraneoplastic syndromes or associated endocrine disorders—are included when clinically appropriate and documented by the treating physician.
The ICD-10 diagnosis codes for bladder cancer types discussed throughout this guide collectively support clinical decision-making, reimbursement accuracy, and public health data quality. Selecting the most specific code available, grounding that selection in pathology and operative documentation, and understanding the in situ versus invasive distinction are the cornerstones of compliant and precise bladder cancer coding in ICD-10-CM.
Frequently Asked Questions
What is the difference between C67.9 and other C67 codes?
C67.9 is used only when the bladder subsite is not documented anywhere in the clinical record. All other C67 codes (C67.0–C67.8) specify the exact anatomical location of the tumor. Coders should review operative reports, pathology notes, and cystoscopy findings before assigning C67.9, as specificity supports accurate billing, cancer registry data, and clinical quality metrics.
Is carcinoma in situ of the bladder coded under C67?
No. Carcinoma in situ of the bladder is coded as D09.0, not under the C67 category. C67 codes apply to invasive malignancies that have breached the basement membrane. The distinction matters clinically and for reimbursement, since non-invasive in situ lesions are managed differently from muscle-invasive tumors and carry different staging and treatment pathways.
Are there separate ICD-10 codes for metastatic bladder cancer?
Yes. When bladder cancer has spread to other organs, the primary tumor retains its C67 subsite code, and each secondary site is coded separately using C77–C79 codes. For example, metastasis to the lung uses C78.00–C78.02, while metastasis to bone uses C79.51–C79.52. Both the primary and secondary codes should appear in the diagnostic record to fully represent the extent of disease.
